Literature DB >> 18571928

Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives.

Hsu-Shan Huang1, Kuo-Feng Huang, Cho-Lu Li, Yi-Yuan Huang, Yi-Hsuan Chiang, Fong-Chun Huang, Jing-Jer Lin.   

Abstract

Telomerase is important in tumor initiation and cellular immortalization. Given the striking correlations between telomerase activity and proliferation capacity in tumor cells, telomerase had been considered as a potentially important molecular target in cancer therapeutics. A series of 2,7-diamidoanthraquinone were designed and synthesized. They were evaluated for their effects on telomerase activity, hTERT expression, cell proliferations, and cytotoxicity. In the series, compounds (6, 10, 13, 16, 18, 19, 20-22, and 24) showed potent telomerase inhibitory activity, while compounds 19, 21, and 22 activated hTERT expression in normal human fibroblasts. The results indicated that 2,7-diamidoanthraquinones represent an important class of compounds for telomerase-related drug developments. Compounds 8, 16, 18, 26, and 32 were also selected by the NCI for Screening Program and demonstrated high anti-proliferative activity against 60 human cancer cell lines. Structure-activity relationships (SAR) study revealed that the test compounds with side chains two carbon spacer between amido and amine are important structural moiety for telomerase inhibition. Although the exact mechanism of how this amine group contributes to its activity is still unclear, however, the amine group in the extended arm of the bis-substituted anthraquinone might contribute to proper binding to the residues within the grove of G-quadruplex structure. Our results indicated that the 2,7-disubstituted amido-anthraquinones are potent telomerase inhibitors that have the potential to be further developed into novel anticancer chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571928     DOI: 10.1016/j.bmc.2008.05.072

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

Review 1.  Journey of anthraquinones as anticancer agents - a systematic review of recent literature.

Authors:  M Shaheer Malik; Reem I Alsantali; Rabab S Jassas; Abdulrahman A Alsimaree; Riyaz Syed; Meshari A Alsharif; Kulkarni Kalpana; Moataz Morad; Ismail I Althagafi; Saleh A Ahmed
Journal:  RSC Adv       Date:  2021-11-05       Impact factor: 4.036

2.  New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules.

Authors:  Yu-Ru Lee; Dah-Shyong Yu; Ya-Chun Liang; Kuo-Feng Huang; Shih-Jie Chou; Tsung-Chih Chen; Chia-Chung Lee; Chun-Liang Chen; Shih-Hwa Chiou; Hsu-Shan Huang
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

3.  DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.

Authors:  Shiu-Wen Huang; Jin-Cherng Lien; Sheng-Chu Kuo; Tur-Fu Huang
Journal:  Oncotarget       Date:  2016-09-27

4.  Identification of a new class of WNT1 inhibitor: Cancer cells migration, G-quadruplex stabilization and target validation.

Authors:  Lien-Cheng Chang; Tsung-Chih Chen; Shiag-Jiun Chen; Chun-Liang Chen; Chia-Chung Lee; Shih-Hsiung Wu; Yun Yen; Hsu-Shan Huang; Jing-Jer Lin
Journal:  Oncotarget       Date:  2016-10-18

5.  CC12 Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Glioblastoma Cell Lines and Mouse Xenograft Model.

Authors:  Li-Yun Fann; Jui-Hu Shih; Jen-Ho Tseng; Hsu-Shan Huang; Sheng-Huang Hsiao
Journal:  Molecules       Date:  2020-04-14       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.